The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

Ryan Brown; Rebekah Bennett; Clare Crean; Andrew Hindley; Julie McGimpsey; Nicholas Cunningham; Aaron Niblock; Suzanne McPherson; Kathryn Boyd; Allister Foy; Ciaren Graham; Graeme Greenfield; Mary Frances McMullin; Mark A Catherwood

doi:10.1111/bjh.70198

The impact of JAK2^V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

Br J Haematol. 2025 Dec;207(6):2597-2601. doi: 10.1111/bjh.70198. Epub 2025 Oct 24.

Authors

Affiliations

¹ Regional Molecular Diagnostic Service, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
² School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.
³ Haematology Department, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
⁴ Haematology Department, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.
⁵ Haematology Department, Southern Health and Social Care Trust, Craigavon, Northern Ireland, UK.
⁶ Centre for Medical Education, Queens University Belfast, Belfast, Northern Ireland, UK.

Abstract

Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2^V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2^V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).

Keywords: JAK2; myeloproliferative neoplasm; pegylated interferon alpha.

MeSH terms

Adult
Aged
Female
Gene Frequency*
Humans
Interferon-alpha* / administration & dosage
Interferon-alpha* / therapeutic use
Janus Kinase 2* / genetics
Male
Middle Aged
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / genetics
Polyethylene Glycols* / administration & dosage
Polyethylene Glycols* / therapeutic use
Recombinant Proteins / administration & dosage
Recombinant Proteins / therapeutic use

Substances

Janus Kinase 2
Interferon-alpha
JAK2 protein, human
Polyethylene Glycols
peginterferon alfa-2a
Recombinant Proteins